Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus cisplatin versus pemetrexed plus carboplatin as adjuvant chemotherapy after complete resection of stage Ib or II non-small cell lung cancer
2005-002911-26Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Alimta + cisplatin with Alimta + carboplatin (2 arms). Started Oct 2005; status: completed.
02
Drugs
pemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-002911-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002911-26.